Brivaracetam: a new drug in development for epilepsy and neuropathic pain

Bibliography

• Sander JW. The epidemiology of epilepsy revisited. Seizure disorders. Curr Opin Neurol 2003;16:165-70
   PubMed Web of Science ®Google Scholar
• Jallon P, Loiseau P, Loiseau J. Newly diagnosed unprovoked epileptic seizures: presentation at diagnosis in CAROLE study. Epilepsia 2001;42:464-75
   PubMed Web of Science ®Google Scholar
• Forsgren L, Beghi E, Õun A, Sillanpää M. The epidemiology of epilepsy in Europe – systematic review. Eur J Neurol 2005;12:245-53
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Eight Eilat Conference (EILAT VIII). Epilepsy Res 2007;73:1-52
   PubMed Web of Science ®Google Scholar
• Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacol Ther 2007;113:165-83
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9
   PubMed Web of Science ®Google Scholar
• Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand 2006;114:157-68
   PubMed Web of Science ®Google Scholar
• Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: mechanism of action and place in therapy. Drugs 2000;60:1029-59
   PubMed Web of Science ®Google Scholar
• Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999;353:1959-64
   PubMed Web of Science ®Google Scholar
• Margineanu DG, Klitgaard H. Levetiracetam mechanism of action. In: Antiepileptic Drugs, 5th edition. Levy RH, Mattson RH, Meldrum BE, Perucca E, editors. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 419-27
   Google Scholar
• Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000;41:1276-83
   PubMed Web of Science ®Google Scholar
• Cereghino JJ, Biton V, Abou-Khali B, et al. The United States Levetiracetam Study Group. Levetiracetam for partial seizures: results of a double blind randomized clinical trial. Neurology 2000;35:236-42
   Google Scholar
• Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 2003;12:131-5
   PubMed Web of Science ®Google Scholar
• Shorvon SD, Löwenthal A, Janz D, et al. The European Levetiracetam Study Group. Multicenter double-blind, randomized, placebo-controled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000;41:1179-86
   PubMed Web of Science ®Google Scholar
• Klitgaard H, Matagne A, Gobert J, Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998;353:191-206
   PubMed Web of Science ®Google Scholar
• Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia 2001;42(Suppl 4):13-8
   PubMed Web of Science ®Google Scholar
• Kwan P, Sills GJ, Brodie M. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001;90:21-34
   PubMed Web of Science ®Google Scholar
• White HS. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 2003;44(Suppl 7):2-8
   PubMedGoogle Scholar
• Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA and glycine-gated currents. Br J Pharmacol 2002;136:659-72
   PubMed Web of Science ®Google Scholar
• Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci USA 1999;96:15268-73
   PubMed Web of Science ®Google Scholar
• Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101:9861-6
   PubMed Web of Science ®Google Scholar
• Archen L, Differding E, Evarard Y, et al. Synthesis of newer KEPPRA analogs. Drugs Future 2002;27(Suppl A):358
   Google Scholar
• Kenda BM, Matagne AC, Talaga PE, et al. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 2004;47:530-49
   PubMed Web of Science ®Google Scholar
• Pollard JR, French J. Antiepileptic drugs in development. Lancet Neurol 2006;5:1064-7
   PubMed Web of Science ®Google Scholar
• Malawska B, Kulig K. Brivaracetam UCB. Curr Opin Investig Drugs 2005;6:740-6
   PubMedGoogle Scholar
• Lambeng N, Gillard M, Vertongen P, et al. Characterization of 3Hucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord. Eur J Pharmacol 2005;520:70-6
   PubMed Web of Science ®Google Scholar
• Zona C, Pieri M, Klitgaard H, Margineanu DG. UCB 34714, a new pyrrolidone derivative inhibits Na+ currents in rat cortical neurons in culture. Epilepsia 2004;45(Suppl 7):146
   Google Scholar
• Kostyuk PG, Lukyanetz EA, Klitgaard H, Margineanu DG. UCB 34714, a new pyrrolidone derivative without impact on high- and low-voltage activated calcium currents in rat isolated neurons. Epilepsia 2004;45(Suppl 7)
   Google Scholar
• Margineanu DG, Schlobohm I, Klitgaard H. UCB 34714, a new pyrrolidone anticonvulsant, had no effect on voltage-gated potassium currents in cultured mouse hippocampal neurons. Epilepsia 2004;45(Suppl 3):116
   Google Scholar
• Rigo JM, Nguyen L, Hans G, et al. UCB 34714: effect on inhibitory and excitatory neurotransmission. Epilepsia 2004;45(Suppl 3):56
   Google Scholar
• Margineanu DG, Kenda B, Michel P, et al. UCB 34714, a new pyrrolidone derivative: comparison with levetiracetam in hippocampal slice epilepsy models in vitro. Epilepsia 2003;44(Suppl 9):261
   PubMed Web of Science ®Google Scholar
• Margineanu DG, Kenda B, Michel P, et al. UCB 34714, a new pyrroloidone derivative inhibits epieptiform responses in hippocampal slices in vitro. Epilepsia 2003;44(Suppl 8):176
   Google Scholar
• Margineanu D, Klitgaard H. The novel SV2A ligands brivaracetam and seletracetam manifest different effects against the epileptiform markers of field potentials in a “high K+-low Ca2+” rat hipokampal slice model. Epilepsia 2006;47(Suppl3):74-5
   Google Scholar
• Matagne A, Kenda B, Michel P, Klitgaard H. UCB 34714, a new pyrrolidone derivative: comparison with levetiracetam in animal models of chronic epilepsy in vivo. Epilepsia 2003;44(Suppl 9):260-1
   Web of Science ®Google Scholar
• Matagne A, Kenda B, Michel P, Klitgaard H. UCB 34714, a new pyrrolidine derivative suppresses seizures epileptogenesis in animal models of chronic epilepsy in vivo Epilepsia 2003;44(Suppl 8):53-4
   Google Scholar
• Wasterlain C, Suchomelova L, Matagne A, et al. Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia 2005;46(Suppl 8):219-20
   Web of Science ®Google Scholar
• Lamberty Y, Ardid D, Eschalier A, et al. A new pyrrolidone derivative ucb 34714 is effective in neuropathic pain models in rats: comparison to gabapentin. J Pain 2003;4(Suppl 10):53
   Google Scholar
• De Ryck M, Matagne A, Kenda B, et al. Contrasting effects of ucb 34714 and drugs for tremor and sedation in rats. Mov Disord 2004;19(Suppl 9):S443
   Google Scholar
• Rolan P, Pigeolet E, Stockis A. UCB 34714: single and multiple rising dose safety, tolerability, and pharmacokinetics in healthy subjects. Epilepsia 2004;45(Suppl 7):314-5
   PubMedGoogle Scholar
• Sargentini-Maier M, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol 2007;63:680-8
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst Trenite DG, Parain D, et al. Proof of principle in the new AED UCB 34714: use of the photosensitivity model. Epilepsia 2004;45(Suppl 7):309
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst Trenité D, Abou-Khalil B, French J, et al. Proof of principle of the new AED selectracetam (UCB 44212) in the photosensivity model. Epilepsia 2006;47(Suppl 4):161-2
   Google Scholar
• Kastelijn-Nolst Trenité D, Genton P, Prain D, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 2007;69:1027-34
   PubMed Web of Science ®Google Scholar
• French JA, Brodsky A, von Rosenstiel P. Efficacy and tolerability of 5, 20 and 50 mg/day brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset seizures. Epilepsia 2007;48(Suppl 6):400
   PubMed Web of Science ®Google Scholar
• French J, von Rosenstiel P. Efficacy and tolerability of brivaracetam as adjunctive treatment for adults with refractory partial-onset seizures. Epilepsia 2007;48(Suppl 7):78
   PubMedGoogle Scholar
• van Paesschen W, von Rosenstiel P. Efficacy and tolerability of brivaracetam as adjunctive treatment for adults with refractory partial-onset epilepsy. Epilepsia 2007;48(Suppl 7):56-7
   Google Scholar
• van Paesschen W, Brodsky A. Efficacy and tolerability of 50 and 150 mg/day brivaracetam (ucb 34714) as adjunctive treatment in adults with refractory partial-onset epilepsy. Epilepsia 2007;48(Suppl 6):329
   Google Scholar
• Brodsky A, Costantini C, von Rosenstiel P. Safety and tolerability of brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset seizures. Epilepsia 2007;48(Suppl 6):342-3
   PubMedGoogle Scholar
• Rosillon D, Astruc B, Bendahmane S, et al. Brivaracetam thorough QT study: lack of proarrhythmic effect. Epilepsia 2007;48(Suppl 6):329
   Google Scholar
• Otoul C, von Rosenstiel P, Stockis A. Evaluation of the pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with partial-onset seizures. Epilepsia 2007;48(Suppl 6):334
   Google Scholar
• Kuba R, Novotná M, Brázdil J, et al. Long-term levetiracetam treatment of epilepsy patients: clinical audit. Epilepsy Res 2006;72:111-9
   PubMed Web of Science ®Google Scholar
• Rupprecht S, Franke K, Fitzek S, et al. Levetiracetam as a treatment option in non-convulsive status epilepticus. Epilepsy Res 2007;73:238-44
   PubMed Web of Science ®Google Scholar
• Alsaadi TM, Thieman C. Levetiracetam monotherapy for newly diagnosed epilepsy patients. Seizure 2003;12:154-6
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Edrich P, Van Vleymen B, et al. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 2003;53:57-64
   PubMed Web of Science ®Google Scholar
• Bialer M. Pharmacokinetic-based design of new antiepileptic and CNS drugs. Epilepsia 2004;45(Suppl 3):34
   PubMedGoogle Scholar
• Wuttke TV, Lerche H. Novel anticonvulsant drugs targeting voltage-dependent ion channels. Expert Opin Investig Drugs 2006;15:1167-77
   PubMed Web of Science ®Google Scholar
• Klitgaard H. Antiepileptic drug discovery: lessons from the past and future challenges. Acta Neurol Scand 2005;112(Suppl 181):68-72
   Web of Science ®Google Scholar
• Rogawski M. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006;69:273-94
   PubMed Web of Science ®Google Scholar
• Ohyama K, Nakajima M, Nakamura S, et al. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 2000;28:1303-10
   PubMed Web of Science ®Google Scholar
• Wen X, Wang J-S, Backman JT, et al. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 2002;30:631-5
   PubMed Web of Science ®Google Scholar
• Ong C-E, Coulter S, Birkett DJ, et al. The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol 2000;50:573-80
   PubMed Web of Science ®Google Scholar
• Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 2005;45:68-78
   PubMed Web of Science ®Google Scholar
• Baulac M. The concept of rare or orphan diseases in epilepsy. Epilepsia 2006;47(Suppl 3):238
   Google Scholar
• van Rosenstiel P. Overview of brivaracetam for progressive myoclonic epilepsies (UCB). Epilepsia 2006;47(Suppl 3):238
   Google Scholar
• Bialer M, Walker MC, Sander JW. Pros and cons for the development of new antiepileptic drugs. CNS Drugs 2002;16:285-9
   PubMed Web of Science ®Google Scholar